Patents by Inventor Matthew Angel

Matthew Angel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240141372
    Abstract: The present disclosure provides compositions and methods for producing transgenic banana plants that exhibit increased resistance to Fusarium oxysporum f.sp. cubense Tropical Race 4 (TR4), and the banana plants and bananas so produced.
    Type: Application
    Filed: September 19, 2023
    Publication date: May 2, 2024
    Inventors: Matthew DiLeo, Jack Q. Wilkinson, Daniel Stauffer, Tomas Hasing, Tengfang Huang, Taylor Frazier-Douglas, Maria Angels de Luis Balaguer, Fayaz Khazi
  • Publication number: 20240143482
    Abstract: A computing platform may be configured with technology for presenting information about a given runtime session of a given client application in the form of a timeline view comprising a time-sorted listing of line items for log events recorded during the given runtime session, wherein each log event's line item includes (i) timing information, (ii) a textual descriptor log event, and (iii) an indication of one or more contextual values associated with the respective log event.
    Type: Application
    Filed: October 31, 2022
    Publication date: May 2, 2024
    Inventors: Brendan Gonzales Lim, Taggart C. Matthiesen, Vicky Li, Martin Conte Mac Donell, Matthew David Klein, Miguel Angel Juarez Lopez
  • Patent number: 11904023
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: February 20, 2024
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Publication number: 20240035025
    Abstract: The present disclosure relates, in part, to circular RNAs and engineered variants thereof.
    Type: Application
    Filed: October 3, 2023
    Publication date: February 1, 2024
    Inventors: Matthew ANGEL, Christopher ROHDE, Aisha SVIHLA
  • Publication number: 20230373903
    Abstract: The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.
    Type: Application
    Filed: July 31, 2023
    Publication date: November 23, 2023
    Inventors: Matthew ANGEL, Franklin KOSTAS, Christopher ROHDE
  • Patent number: 11814333
    Abstract: The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: November 14, 2023
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Franklin Kostas, Christopher Rohde
  • Publication number: 20230323399
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Application
    Filed: June 9, 2023
    Publication date: October 12, 2023
    Inventors: Matthew ANGEL, Christopher ROHDE
  • Publication number: 20230304044
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Application
    Filed: June 9, 2023
    Publication date: September 28, 2023
    Inventors: Matthew ANGEL, Christopher ROHDE
  • Publication number: 20230242943
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Application
    Filed: August 22, 2022
    Publication date: August 3, 2023
    Inventors: Matthew ANGEL, Christopher ROHDE
  • Patent number: 11708586
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: July 25, 2023
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11692203
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: July 4, 2023
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Publication number: 20230193231
    Abstract: The present invention relates in part to nucleic acids encoding gene editing proteins, including novel engineered variants.
    Type: Application
    Filed: October 11, 2022
    Publication date: June 22, 2023
    Inventors: Matthew ANGEL, Franklin KOSTAS, Mitchell KOPACZ, Christopher ROHDE
  • Publication number: 20230193207
    Abstract: Cell-based therapies based on mesenchymal stem cells (MSCs) are described.
    Type: Application
    Filed: October 14, 2022
    Publication date: June 22, 2023
    Inventors: Matthew Angel, Christopher Rohde, Jasmine Harris
  • Publication number: 20230151335
    Abstract: The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.
    Type: Application
    Filed: October 3, 2022
    Publication date: May 18, 2023
    Inventors: Matthew ANGEL, Christopher ROHDE
  • Publication number: 20230033888
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Application
    Filed: August 5, 2022
    Publication date: February 2, 2023
    Inventors: Matthew ANGEL, Christopher ROHDE
  • Publication number: 20230015146
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Application
    Filed: August 17, 2022
    Publication date: January 19, 2023
    Inventors: Matthew ANGEL, Christopher ROHDE
  • Patent number: 11492600
    Abstract: The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: November 8, 2022
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11466293
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: October 11, 2022
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Publication number: 20220243228
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Application
    Filed: April 12, 2022
    Publication date: August 4, 2022
    Inventors: Matthew ANGEL, Christopher ROHDE
  • Patent number: 11339409
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: May 24, 2022
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde